Sanofi-Aventis Loses Patent Lawsuit In Korea Over Oxaliplatin
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Sanofi-Aventis lost a patent lawsuit in South Korea, after the country's Supreme Court dismissed its appeal to nullify patents obtained by Korea-based Boryung Pharmaceutical for its generic drug for colorectal cancer, Boryung announced Oct. 20
You may also be interested in...
Korea's Supreme Court Upholds Lower Courts' Ruling against Pfizer's Lipitor Patent Extension
SEOUL - Ending nearly two years of court battles over the patent extension of Pfizer's cholesterol drug Lipitor, South Korea's Supreme Court upheld the lower courts' rulings in favor of six local Korean pharmaceutical companies that have been selling generics of Lipitor (atorvastatin)
Korea's Supreme Court Upholds Lower Courts' Ruling against Pfizer's Lipitor Patent Extension
SEOUL - Ending nearly two years of court battles over the patent extension of Pfizer's cholesterol drug Lipitor, South Korea's Supreme Court upheld the lower courts' rulings in favor of six local Korean pharmaceutical companies that have been selling generics of Lipitor (atorvastatin)
Disputes Between South Korean Local Drug Makers And Multinationals Increasing, Expected To Get Worse
Pending free trade agreement gives multinationals 20 years of patent protection, a long wait to make generics.